Health care stocks have been on a run lately, leading the S&P 500’s 11 sectors over the past three months with a gain of ...

Pfizer Inc. pulled off a comeback win, beating out Danish drug giant Novo Nordisk to acquire obesity drug developer Metsera Inc. in a deal that values the biotechnology company at up to $9.1 billion.

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

Yao Pharma's deal with the US pharmaceutical giant underscores China's growing role in global biotech licensing US ...

Last April, neuroscientist Sue Grigson received an e-mail from a man detailing his years-long struggle to kick addiction — first to opioids, and then to the very medication meant to help him quit. The ...

Share on Pinterest The WHO recommended GLP-1s as a treatment for obesity alongside a healthy diet and regular exercise. Milles Team/Stocksy New guidelines from the World Health Organization (WHO) ...

The WHO issued new guidelines endorsing GLP-1 receptor agonists for the long-term treatment of obesity in adults. GLP-1 drugs must be combined with counseling on behavioral and lifestyle changes, the ...

The World Health Organization issued new guidelines Monday recommending the use of GLP-1 drugs for treating obesity. In the new guidelines, the United Nations health agency made two key ...

Dec 1 (Reuters) - Eli Lilly (LLY.N), opens new tab said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S.

The World Health Organization on Monday recommended GLP-1 drugs as a tool to manage obesity in adults, marking a shift in the way the U.N. agency has historically framed obesity treatment. The WHO ...